Getting a Drug from Bench to Bedside: The MHRA and NICE Processes
Home / Getting a Drug from Bench to Bedside: The MHRA and NICE Processes
Getting a Drug Approved for Use on the NHS
These are exciting times for those living with FOP and what we have all been waiting for. We now have two potential treatments for FOP which have received FDA approval. This means that pharmaceutical companies will soon be applying to the UK’s MHRA and NICE for licensing and access approval, which will make them available for prescription on the NHS.
We have broken down the process, including how the two bodies work and their different roles, so you can clearly understand where new treatments stand and what lies ahead for our community.
The role of the patient voice in this process is critical; without it, getting treatments approved and accessible simply cannot happen. Here, we outline the vital role you, our patients and families, can play to give us all the best chance of securing available treatments for FOP.
Across the UK, each of our four nations has its own system for making new treatments available through the NHS. While the MHRA licenses medicines nationwide and NICE evaluates treatments for England, Scotland, Wales, and Northern Ireland follow their own distinct pathways. Navigating these interconnected systems can feel complex, but ensuring equal access everywhere remains vital.
FOP Friends is committed to working towards approval and access to new treatments in all four nations of the UK. We will continue to work with patients, families, healthcare professionals, and decision-makers to ensure that the needs and experiences of our community are heard throughout this process.
Our aim is to give everyone living with FOP across the UK the best possible chance of accessing new treatments through the NHS.
The National Institute for Health and Care Excellence (NICE) is the public body responsible for evaluating new medicines for both NHS England and NHS Wales.
One of NICE’s primary roles is to assess how well new drugs work and decide whether the NHS should fund them, ensuring patients gain access to effective treatments.
Presenter: Professor Richard Keen, Royal National Orthopaedic Hospital
Following recent positive clinical trial results, Regeneron and Incyte/Mirum are advancing their respective applications for market approval in the USA.
Professor Richard Keen will discuss what these developments mean for patients and families across the UK. He will outline the pathways pharmaceutical companies must navigate to achieve UK market access, beginning with regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA), moving through the role of the National Institute for Health and Care Excellence (NICE), and specifically highlighting the Highly Specialised Technologies (HST) evaluation process. Finally, he will explain how these medicines ultimately reach patients through NHS England funding and commissioning frameworks.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.